E2F3 and breast cancer: Across the 16 TUR samples, we detected focal CDKN2A loss (37. 5%), E2F3/SOX4 gain (37. 5%), PPARG gain (25. 0%), YWHAZ gain (18. 8%), CREBBP loss (12. 5%), MYCL1 gain (12. 5%) and CNAs of other BC genes, as previously shown24.